CYTR - CytRx Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

CytRx Corporation

11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
310-826-5648
http://www.cytrx.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Mr. Steven A. KriegsmanChairman & CEO1.01MN/A1942
Mr. John Y. CalozChief Financial Officer535kN/A1952
Mr. Eric L. CurtisPres & COON/AN/AN/A
Dr. Felix Kratz Ph.D.Sr. VP, Drug Devel.N/AN/A1963
Dr. André Warnecke Ph.D.Sr. Director of Drug DiscoveryN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Corporate Governance

CytRx Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.